CNSP Key Statistics, Chart & Performance
The current stock price of CNSP is 6.2 USD. In the past month the price decreased by -8.28%. In the past year, price decreased by -90.85%.
CNSP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.98 | 1.02T | ||
| JNJ | JOHNSON & JOHNSON | 20.02 | 500.60B | ||
| MRK | MERCK & CO. INC. | 12.08 | 264.21B | ||
| PFE | PFIZER INC | 7.82 | 142.31B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.34 | 111.38B | ||
| ZTS | ZOETIS INC | 19.79 | 55.30B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.55 | 22.66B | ||
| VTRS | VIATRIS INC | 5.25 | 14.10B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.31 | 11.12B | ||
| CORT | CORCEPT THERAPEUTICS INC | 94.99 | 8.79B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.74B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.41B |
Related stock screener links
About CNSP
Company Profile
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Company Info
CNS PHARMACEUTICALS INC
2100 West Loop S Ste 900
Houston TEXAS 77027 US
CEO: John Climaco
Employees: 5
Phone: 18009469185
CNS PHARMACEUTICALS INC / CNSP FAQ
What does CNSP do?
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. The company is headquartered in Houston, Texas and currently employs 4 full-time employees. The company went IPO on 2019-11-08. The firm's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The firm's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
What is the stock price of CNS PHARMACEUTICALS INC today?
The current stock price of CNSP is 6.2 USD. The price decreased by -0.48% in the last trading session.
What is the dividend status of CNS PHARMACEUTICALS INC?
CNSP does not pay a dividend.
What is the ChartMill technical and fundamental rating of CNSP stock?
CNSP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for CNS PHARMACEUTICALS INC?
CNS PHARMACEUTICALS INC (CNSP) operates in the Health Care sector and the Pharmaceuticals industry.
Should I buy CNSP stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CNSP.
CNSP Technical Analysis
CNSP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CNSP. While CNSP seems to be doing ok healthwise, there are quite some concerns on its profitability.
CNSP Financial Highlights
Over the last trailing twelve months CNSP reported a non-GAAP Earnings per Share(EPS) of -130.83. The EPS increased by 99.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -110.13% | ||
| ROE | -131.9% | ||
| Debt/Equity | 0 |
CNSP Forecast & Estimates
8 analysts have analysed CNSP and the average price target is 53.04 USD. This implies a price increase of 755.48% is expected in the next year compared to the current price of 6.2.